CoChat

Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment

Open access
Antos, Zuzanna, Żukow, Xawery, Bursztynowicz, Laura, Jakubów, Piotr · 2024 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.

Abstract

The rising prevalence of depression, with its associated suicide risk, demands effective fast-acting treatments. Ketamine has emerged as promising, demonstrating rapid antidepressant effects. While early studies show swift mood improvements, its precise mechanisms remain unclear. This article aims to compile and synthesize the literature on ketamine’s molecular actions. Ketamine primarily works by antagonizing NMDA receptors, reducing GABAergic inhibition, and increasing glutamate release. This enhanced glutamate activates AMPA receptors, triggering crucial downstream cascades, including BDNF-TrkB and mTOR pathways, promoting synaptic proliferation and regeneration. Moreover, neuroimaging studies have demonstrated alterations in brain networks involved in emotional regulation, including the Default Mode Network (DMN), Central Executive Network (CEN), and Salience Network (SN), which are frequently disrupted in depression. Despite the promising findings, the literature reveals significant inaccuracies and gaps in understanding the full scope of ketamine’s therapeutic potential. For instance, ketamine engages with opioid receptors, insinuating a permissive role of the opioid system in amplifying ketamine’s antidepressant effects, albeit ketamine does not operate as a direct opioid agonist. Further exploration is requisite to comprehensively ascertain its safety profile, long-term efficacy, and the impact of genetic determinants, such as BDNF polymorphisms, on treatment responsiveness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms252413658

Cites

224 of 224 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flowchart of search strategy. * Due to frequent gaps in the PubMed database regarding selected molecular aspects, we included older studies if, after consultation between three authors, the study was deemed crucial (three authors indicated “yes” during the inclusion voting (“yes” or “no”). Additionally, we used ResearchGate for topics that were not sufficiently covered by data exclusively from PubMed. ** In this step, despite excluding studies that did not meet our inclusion criteria, we removed duplicate studies missed by the automated tool.
Figure 1 Flowchart of search strategy. * Due to frequent gaps in the PubMed database regarding selected molecular aspects, we included older studies if, after consultation between three authors, the study was deemed crucial (three authors indicated “yes” during the inclusion voting (“yes” or “no”). Additionally, we used ResearchGate for topics that were not sufficiently covered by data exclusively from PubMed. ** In this step, despite excluding studies that did not meet our inclusion criteria, we removed duplicate studies missed by the automated tool.CC BY · PubMed Central
Figure 2 Pathway of 1 phase ketamine metabolism. Ketamine (both isomers) is metabolized through N-demethylation by liver cytochrome P450 enzymes (primarily by CYP3A4 and CYP2B6), resulting in the formation of norketamine. Norketamine is then mainly converted by CYP2B6, CYP3A5 and CYP2A6 through hydroxylation to hydroxynorketamine (right path) and by CYP2B6 through dehydrogenation to dehydronorketamine (left path).
Figure 2 Pathway of 1 phase ketamine metabolism. Ketamine (both isomers) is metabolized through N-demethylation by liver cytochrome P450 enzymes (primarily by CYP3A4 and CYP2B6), resulting in the formation of norketamine. Norketamine is then mainly converted by CYP2B6, CYP3A5 and CYP2A6 through hydroxylation to hydroxynorketamine (right path) and by CYP2B6 through dehydrogenation to dehydronorketamine (left path).CC BY · PubMed Central
Figure 3 Ketamine blocks NMDA receptors on GABA-releasing interneurons (A), reducing GABA release from presynaptic glutamatergic neuron (B). Reduction in HCN1 activity promotes increased glutamate release. Glutamate activates AMPA receptors at a postsynaptic neuron (C), which initiates a cascade of intracellular events involving the mTOR pathway, elevating BDNF levels. The activation of mTOR is linked to increased phosphorylation of the proteins 4E-BP1 and p70S6K. Elevated BDNF levels activate TrkB receptors, activating TRPC3 through the TrkB-PLCγ pathway. Additionally, BDNF indirectly triggers rapid activation of the PI3K-Akt pathway, stabilizing the interaction between PSD-95 and TrkB to facilitate synaptic connectivity. TrkB modulates NMDA receptor activity by dissociating RasGrf1 from NR2B, reducing NMDA receptor signaling associated with LTD. Blockade of NMDA receptors also reduces phosphorylation of eEF2, which, in turn, enhances BDNF expression. Akt activation further influences cellular processes by inhibiting the TSC2 protein, releasing mTORC1 from regulatory constraints, and enhancing mTORC1 signaling. (2R,6R)-HNK dissociates TrkB from PTPσ, restoring juvenile-like plasticity in the brain. Additionally, ketamine administration restores GLT-1 levels in astrocytes (D), supporting glutamate reuptake and regulation. Activation of the ERα receptor initiates a positive feedback loop in which ketamine enhances the effects of its metabolites by increasing the activity of the enzymes CYP2A6 and CYP2B6.
Figure 3 Ketamine blocks NMDA receptors on GABA-releasing interneurons (A), reducing GABA release from presynaptic glutamatergic neuron (B). Reduction in HCN1 activity promotes increased glutamate release. Glutamate activates AMPA receptors at a postsynaptic neuron (C), which initiates a cascade of intracellular events involving the mTOR pathway, elevating BDNF levels. The activation of mTOR is linked to increased phosphorylation of the proteins 4E-BP1 and p70S6K. Elevated BDNF levels activate TrkB receptors, activating TRPC3 through the TrkB-PLCγ pathway. Additionally, BDNF indirectly triggers rapid activation of the PI3K-Akt pathway, stabilizing the interaction between PSD-95 and TrkB to facilitate synaptic connectivity. TrkB modulates NMDA receptor activity by dissociating RasGrf1 from NR2B, reducing NMDA receptor signaling associated with LTD. Blockade of NMDA receptors also reduces phosphorylation of eEF2, which, in turn, enhances BDNF expression. Akt activation further influences cellular processes by inhibiting the TSC2 protein, releasing mTORC1 from regulatory constraints, and enhancing mTORC1 signaling. (2R,6R)-HNK dissociates TrkB from PTPσ, restoring juvenile-like plasticity in the brain. Additionally, ketamine administration restores GLT-1 levels in astrocytes (D), supporting glutamate reuptake and regulation. Activation of the ERα receptor initiates a positive feedback loop in which ketamine enhances the effects of its metabolites by increasing the activity of the enzymes CYP2A6 and CYP2B6.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 224 references

Research works printed but not linked: 2

  1. Delgado, 2000, Depression: The case for a monoamine deficiency, J. Clin. Psychiatry, 61, 7
  2. Depukat, 2024, Polski standard leczenia racemiczną ketaminą pacjentów z zaburzeniami depresyjnymi opracowany przez zespół roboczy powołany przez Konsultanta Krajowegow dziedzinie psychiatrii, Psychiatr. Pol., 58, 377

Metadata

Authors
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P.
Affiliations
Medical University of Białystok (PL)
Corresponding author
Jakubów, Piotr
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2024-12-20
Volume
25
Issue
24
Pages
13658
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4405695206
Cited by
21
References
224
Citations by year
2026: 15 · 2025: 6
FWCI
1.31
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
ketamine, depression, rapid-acting antidepressants, NMDA receptor antagonism, glutamate, AMPA receptors, BDNF/TrkB signaling, mTOR signaling, synaptic plasticity, default mode network, frontoparietal network, salience network, opioid receptors, BDNF polymorphism, treatment response
MeSH terms
Animals, Antidepressive Agents, Brain, Depression, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Brain-Derived Neurotrophic Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment. https://app.cochat.ai/papers/10.3390/ijms252413658
The paper
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024). Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413658

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.